Mega-epsilon waves on 12-lead ECG--just another case of arrhythmogenic right ventricular dysplasia/cardiomyopathy?

Epsilon wave, the post-excitation small squiggles at the beginning of ST segment that first named by Fontaine, is a well-known ECG phenomenon frequently associated with arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C). Epsilon waves are caused by post excitation of the myocytes in the right ventricle due to myocardial scaring. Increasing evidence suggests that cardiac sarcoidosis might produce the pathological substrate required for production of epsilon waves.

Electrical failure of an ICD lead due to a presumed insulation defect only diagnosed by a maximum output shock.

A 55-year-old male patient presented after a single shock caused by oversensing of isolated nonphysiologic signals on both the distal HV and pace-sense channels. No other abnormalities were found. He subsequently returned complaining of device "vibration" and his St.

Cardiogenic shock: collaboration between cardiac surgery and cardiology subspecialties to bridge to recovery.

Acute cardiogenic shock is a lethal condition that results in death from myocardial failure, arrhythmia, or combinations of both. Aggressive medical, surgical, and interventional maneuvers have helped reduce the mortality. For the most advanced cases, ventricular assist devices have been used for persistent shock states.

Cardiac resynchronization therapy and other new approaches for the treatment of heart failure in the elderly.

Approximately 15% to 20% of patients with systolic heart failure have a QRS duration greater than 120 ms, which is most commonly seen as left bundle-branch block (LBBB). In LBBB, the left ventricle is activated through the septum from the right ventricle, resulting in a significant delay between the onset of right (RV) and left ventricular (LV) contraction. In patients with LV dysfunction, ventricular dyssynchrony caused by LBBB places the already failing left ventricle at an additional mechanical disadvantage.

Pharmacologic therapies for atrial fibrillation.

Pharmacologic therapy for atrial fibrillation may be used for acute cardioversion or ventricular rate control or for long-term therapy to maintain sinus rhythm or control ventricular rates in atrial fibrillation. Therapies must be tailored to elderly patients, with particular attention to structural heart disease, bradycardia, hypotension, and other comorbidities, including renal or hepatic insufficiency. Such considerations may dictate the use or avoidance of certain agents.

Cardiac Resynchronization Therapy for Heart Failure.

Cardiac resynchronization therapy has been established as important adjuvant therapy in the treatment of severe heart failure. As lead delivery systems have improved and the number of experienced implanters has increased, more patients have access to transvenous left ventricular lead implantation, outside of clinical trials at large medical centers. Ongoing research continues to perfect implantation techniques to optimize patient outcomes, as well as develop hardware and software technology used in implanted devices.

Overview of the management of atrial fibrillation: what is the current state of the art?

Management of Atrial Fibrillation. There are three fundamental approaches to the management of atrial fibrillation (AF): rate control, rhythm control, and anticoagulation. Selecting a course of treatment requires a thorough knowledge of these therapeutic alternatives.

Elevations in ventricular pacing threshold with the use of the Y adaptor: implications for biventricular pacing.

Cardiac resynchronization therapy (CRT) is a new and promising therapeutic option for patients with severe heart failure and intraventricular conduction delay. Patients who are candidates for CRT and have a previously implanted device may utilize a "Y" IS 1 connector to accommodate the coronary sinus lead. This modification has the potential to alter biventricular pacing thresholds.

Effect of cardiac resynchronization therapy on left ventricular size and function in chronic heart failure.

Background: Cardiac resynchronization therapy (CRT) has recently emerged as an effective treatment for patients with moderate to severe systolic heart failure and ventricular dyssynchrony. The purpose of the present study was to determine whether improvements in left ventricular (LV) size and function were associated with CRT.

Methods And Results: Doppler echocardiograms were obtained at baseline and at 3 and 6 months after therapy in 323 patients enrolled in the Multicenter InSync Randomized Clinical Evaluation (MIRACLE) trial.

Alcohol septal ablation complicated by complete heart block and permanent pacemaker failure.

Alcohol septal ablation is a novel catheter-based technique for the treatment of obstructive hypertrophic cardiomyopathy. Complete heart block complicates the procedure in 7%-30% of cases and necessitates the prophylactic insertion of a temporary pacing wire in all patients who do not have a permanent pacemaker. We describe a case of alcohol septal ablation complicated by complete heart block and failure to capture by both a permanent pacemaker and an implantable cardioverter defibrillator (ICFD) with pacing capabilities.

Cardiac resynchronization in chronic heart failure.

Background: Previous studies have suggested that cardiac resynchronization achieved through atrial-synchronized biventricular pacing produces clinical benefits in patients with heart failure who have an intraventricular conduction delay. We conducted a double-blind trial to evaluate this therapeutic approach.

Methods: Four hundred fifty-three patients with moderate-to-severe symptoms of heart failure associated with an ejection fraction of 35 percent or less and a QRS interval of 130 msec or more were randomly assigned to a cardiac-resynchronization group (228 patients) or to a control group (225 patients) for six months, while conventional therapy for heart failure was maintained.